Cincinnati Children's Hospital Medical Center

University of Cincinnati

Children's Medical Center Corporation

The State University of New York

St. Jude Children's Research Hospital

Universitaet Ulm

Girindus America, Inc.

Universitat Ulm

Platefuse, Inc.

Yi Zheng

David A Williams

Jose Cancelas

Prakash Jagtap

Jaroslaw Meller

Marie-Dominique Filippi

Emily E Bosco

Wieslaw Adam Mazur

Jie Zheng

Nicolas Nassar

Matthew Wortman

Maria Carolina Florian

Hartmut Geiger

Karlheinz R Skowronek

Huzoor Akbar

Yuan Gao

John B Dickerson

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

Platelet storage methods and compositions for same

The present invention relates generally to methods and pharmaceutical compositions for rejuvenating hematopoietic stem cells and progenitor cells from blood, intestinal tissue and dermal tissue by administration of at least one inhibitor of a GT-Pase, such as Cdc42 GTPase.

Rejuvenation of precursor cells

Provided are inhibitors of Rho GTPase activation, and, in particular, compounds that inhibit RhoA activation by an RhoGEF. Also provided are related pharmaceutical compositions and methods. Also provided are methods of inhibiting Rho GTPase activation. Also provided are methods of screening for compounds that inhibit Rho GTPase activation by a RhoGEF.

Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors

Inhibitors of p67protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.

[object Object]

Inhibitors of p67protein are provided herein, as well as pharmaceutical compositions and methods recited thereto.

Use of small molecule inhibitors targeting the interaction between Rac GTPase and p67 (phox)

Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject.

Mobilization of hematopoietic stem cells

Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.

Chimeric peptides for the regulation of GTPases

The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.

Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE

GTPase inhibitors and use thereof for controlling platelet hyperactivity

Growing community of inventors

Cincinnati, OH, United States of America

Yi Zheng